No Data
No Data
Hong Kong stock concept tracking | The Ministry of Industry and Information Technology has issued a document! Regarding the brain-computer interface, institutions: Focus on the possibility of implementing scenarios (with concept stocks attached)
Tianfeng Securities believes that the brain-computer interface market has broad potential, frequent encouragement policies, and diverse application scenarios.
Hong Kong Stock Concept Tracking | New Advances in Brain-Computer Interface Technology! Neuralink begins recruiting a second patient (with concept stock)
Musk announced that after 100 days of successful surgery for the first patient involved in the brain-computer device implantation experiment at the beginning of the year, Neuralink (Neuralink) has officially begun recruiting a second patient to receive a brain-computer implantation.
Zhongtai Securities: Steady performance under the influence of policies and fundamentals, grasping investment opportunities driven by medical device innovation+ inflection points
The medical device industry continues to grow rapidly. It is optimistic about importation substitution and global development driven by innovation. Volume procurement policies will continue to be implemented, medical anti-corruption is expected to ease, and sector valuations are expected to gradually recover.
心瑋醫療-B:年度報告 2023
Interpretation of Xinwei Medical-B (6609.HK) Annual Report: Innovation and Globalization, Therapeutic Products Save Development Potential
The concept of “new quality productivity” was emphasized many times during the two sessions. In particular, the medical device industry, the high-end medical device sector, which is driven by scientific and technological innovation as the core driving force, is undoubtedly also moving towards a rapid development path as an important indicator for measuring the country's level of high-tech development.
Xinwei Medical-B (06609.HK) announced annual results: business focus on driving product structure transformation, gross margin rose to 70.5%, losses narrowed, and major neurointerventional treatment devices are about to be launched
Gelonghui March 28 | Xinwei Medical-B (06609.HK) announced its annual results. For the year ended December 31, 2023, the company's revenue increased to RMB 232.3 million, an increase of 26.9% year on year, and loss before tax narrowed to RMB 102.9 million, a year-on-year decrease of 48.9%. With the expansion of business scale and the effects of cost control and efficiency measures, the company's gross margin increased 2.6 percentage points to 70.5%, and the share of sales and distribution expenses and administrative expenses decreased to 66.2% (2022:91.8%). In 2023, in order to adapt to a rapidly changing city
No Data